Medicine and Dentistry
Prostate Cancer
100%
Neoplasm
48%
Prostatectomy
48%
Clear Cell Renal Cell Carcinoma
47%
Cystectomy
29%
Recurrent Disease
26%
Diseases
25%
Metastatic Carcinoma
24%
Malignant Neoplasm
24%
Prostate Specific Antigen
20%
Radiation Therapy
19%
Bladder Cancer
18%
Kidney Tumour
18%
Cancer Specific Survival
16%
Transitional Cell Carcinoma
15%
Nephrectomy
15%
Retroperitoneal Lymph Node Dissection
14%
Overall Survival
13%
Biochemical Recurrence
12%
Radical Nephrectomy
12%
Partial Nephrectomy
12%
Biopsy Technique
12%
Hazard Ratio
11%
Androgen
11%
Lymph Node
11%
Gleason Score
11%
Bladder
11%
Androgen Receptor
10%
Biological Marker
8%
Proportional Hazards Model
8%
Pelvis
8%
Cryoablation
8%
Androgen Deprivation Therapy
7%
T Cell
7%
Immunotherapy
7%
Cancer
7%
Systematic Review
6%
Cancer Cell
6%
Magnetic Resonance Imaging
6%
Kidney Metastasis
6%
Odds Ratio
5%
Primary Tumor
5%
Cancer Growth
5%
Progression Free Survival
5%
Kidney Cancer
5%
Lymph Node Metastasis
5%
Keyphrases
Prostate Cancer
72%
Radical Prostatectomy
40%
Renal Cell Carcinoma
37%
Tumor
32%
Radical Cystectomy
26%
Androgen Receptor
24%
Prostate-specific Antigen
22%
Bladder Cancer
19%
Cancer-specific Survival
18%
Androgens
16%
Clear Cell Renal Cell Carcinoma (ccRCC)
15%
Programmed Death-ligand 1 (PD-L1)
14%
Oncological Outcomes
13%
Nephrectomy
13%
Hazard Ratio
13%
Confidence Interval
13%
Radical Nephrectomy
12%
Overall Survival
12%
Biochemical Recurrence
12%
Partial Nephrectomy
11%
Metastasis
11%
Androgen Deprivation Therapy
11%
B7-H1
11%
Prostate
10%
Cancer Mortality
10%
Prostate Cancer Cells
10%
High-grade Prostate Cancer
10%
Upper Tract Urothelial Carcinoma
9%
Metastatic Renal Cell Carcinoma (mRCC)
9%
Renal Tumor
9%
High Risk
9%
Extracellular Vesicles
7%
T Cells
7%
Gleason Score
6%
Mayo Clinic
6%
Prostate Cancer Patients
6%
Radiation Therapy
6%
Recurrent Prostate Cancer
6%
Multivariable
6%
Clinical Outcomes
6%
Renal Mass
6%
Odds Ratio
6%
Urothelial Carcinoma
6%
Prostatectomy
5%
Castration-resistant Prostate Cancer
5%
Disease Progression
5%
Prostate Cancer Risk
5%
Distant Metastasis
5%
CD8+ T Cells
5%
Tumor Size
5%
Metastatic Disease
5%
Primary Tumor
5%
Prostate Cancer Progression
5%